title: Salmeterol Efficacy and Bias in the Activation and Kinase-Mediated Desensitization of β2-Adrenergic Receptors.
abstract: Salmeterol is a long-acting β2-adrenergic receptor (β2AR) agonist that is widely used as a bronchodilator for the treatment of persistent asthma and chronic obstructive pulmonary disease in conjunction with steroids. Previous studies demonstrated that salmeterol showed weak efficacy for activation of adenylyl cyclase; however, its efficacy in the complex desensitization of the β2AR remains poorly understood. In this work, we provide insights into the roles played by the G protein-coupled receptor kinase/arrestin and protein kinase A in salmeterol-mediated desensitization through bioluminescence resonance energy transfer (BRET) studies of liganded-β2AR binding to arrestin and through kinetic studies of cAMP turnover. First, BRET demonstrated a much reduced efficacy for salmeterol recruitment of arrestin to β2AR relative to isoproterenol. The ratio of BRETISO/BRETSALM after 5-minute stimulation was 20 and decreased to 5 after 35 minutes, reflecting a progressive decline in BRETISO and a stable BRETSALM. Second, to assess salmeterol efficacy for functional desensitization, we examined the kinetics of salmeterol-induced cAMP accumulation (0-30 minutes) in human airway smooth muscle cells in the presence and absence of phosphodiesterase inhibition. Analysis of shaping of cAMP turnover for both agonists demonstrated significant salmeterol desensitization, although it was reduced relative to isoproterenol. Using an isoproterenol rescue protocol after either short-term (10 minutes) or long-term (2 and 14 hours) salmeterol pretreatments, we found that salmeterol progressively depressed isoproterenol stimulation but did not prevent subsequent rescue by isoproterenol and additional isoproterenol-mediated desensitization. Our findings reveal a complex efficacy for functional desensitization, demonstrating that although salmeterol shows weak efficacy for adenylyl cyclase activation and G protein-coupled receptor kinase/arrestin-mediated desensitization, it acts as a strong agonist in highly amplified protein kinase A-mediated events.
authors.affiliation: Department of Pharmacology, Vanderbilt University Medical Center, Nashville, Tennessee (L.E.G.); Division of Internal Medicine, Department of Symptom Research, University of Texas MD Anderson Cancer Center, Houston, Texas (F.B.); and Department of Integrative Biology and Pharmacology, University of Texas Health Science Center, Houston, Texas (S.J.V., R.B.C.).
authors.forename: Luis E
authors.initials: LE
authors.lastname: Gimenez
authors.affiliation: Department of Pharmacology, Vanderbilt University Medical Center, Nashville, Tennessee (L.E.G.); Division of Internal Medicine, Department of Symptom Research, University of Texas MD Anderson Cancer Center, Houston, Texas (F.B.); and Department of Integrative Biology and Pharmacology, University of Texas Health Science Center, Houston, Texas (S.J.V., R.B.C.).
authors.forename: Faiza
authors.initials: F
authors.lastname: Baameur
authors.affiliation: Department of Pharmacology, Vanderbilt University Medical Center, Nashville, Tennessee (L.E.G.); Division of Internal Medicine, Department of Symptom Research, University of Texas MD Anderson Cancer Center, Houston, Texas (F.B.); and Department of Integrative Biology and Pharmacology, University of Texas Health Science Center, Houston, Texas (S.J.V., R.B.C.).
authors.forename: Sharat J
authors.initials: SJ
authors.lastname: Vayttaden
authors.affiliation: Department of Pharmacology, Vanderbilt University Medical Center, Nashville, Tennessee (L.E.G.); Division of Internal Medicine, Department of Symptom Research, University of Texas MD Anderson Cancer Center, Houston, Texas (F.B.); and Department of Integrative Biology and Pharmacology, University of Texas Health Science Center, Houston, Texas (S.J.V., R.B.C.) richard.b.clark@uth.tmc.edu.
authors.forename: Richard B
authors.initials: RB
authors.lastname: Clark
mesh_terms: D015105:3',5'-Cyclic-AMP Phosphodiesterases / Q000037:antagonists & inhibitors; D000318:Adrenergic beta-Agonists / Q000494:pharmacology*; D000420:Albuterol / Q000031:analogs & derivatives* / Q000494:pharmacology; D000818:Animals; D019390:Arrestins / Q000378:metabolism; D019556:COS Cells; D002522:Chlorocebus aethiops; D000242:Cyclic AMP / Q000096:biosynthesis; D017868:Cyclic AMP-Dependent Protein Kinases / Q000378:metabolism*; D054768:G-Protein-Coupled Receptor Kinases / Q000378:metabolism*; D006801:Humans; D007545:Isoproterenol / Q000494:pharmacology; D032389:Myocytes, Smooth Muscle / Q000187:drug effects / Q000378:metabolism; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology; D018343:Receptors, Adrenergic, beta-2 / Q000235:genetics / Q000378:metabolism*; D000068299:Salmeterol Xinafoate; D000071557:beta-Arrestins
chemical_list: D000318:Adrenergic beta-Agonists; D019390:Arrestins; D010726:Phosphodiesterase Inhibitors; D018343:Receptors, Adrenergic, beta-2; D000071557:beta-Arrestins; D000068299:Salmeterol Xinafoate; D000242:Cyclic AMP; D017868:Cyclic AMP-Dependent Protein Kinases; D054768:G-Protein-Coupled Receptor Kinases; D015105:3',5'-Cyclic-AMP Phosphodiesterases; D007545:Isoproterenol; D000420:Albuterol